前收市價 | 0.0500 |
開市 | 0.0500 |
買盤 | 0.0000 |
賣出價 | 0.0500 |
拍板 | 140.00 |
到期日 | 2024-05-17 |
今日波幅 | 0.0500 - 0.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 244 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.